Eli Lilly begins $2.5B factory construction in Germany for increased weight-loss drug production, targeting global markets.

Eli Lilly begins $2.5B factory construction in Germany to increase weight-loss drug production, targeting global markets, including Europe. The plant, set to open in 2027, will produce injectable medicines like Zepbound, facing US shortages, and compete with Novo Nordisk for the new generation of injected obesity medicines. The factory will create 1,000 jobs in production, research, and development.